Edwards Lifesciences vs Smith & Nephew
EW and SNN side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EW and SNN compare
Edwards Lifesciences grew revenue faster over the last twelve months (14.6% versus 6.1% for Smith & Nephew).
Edwards Lifesciences scores higher on the StockData Score (10 against 6 for Smith & Nephew), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EW | SNN |
|---|---|---|
| Size and price | ||
| Market cap | $53.0B | – |
| Share price | $92.01 | $29.70 |
| Change, 1 year | 11.3% | −17.0% |
| Change, 5 years | −22.5% | −20.1% |
| Beta (5Y) | 1.00 | 0.63 |
| Employees | 16K | 18K |
| StockData Score | ||
| Total score | 10 (better) | 6 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 3 (better) | 1 |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 52.9× | – |
| P/S | 8.1× | – |
| P/B | 5.0× | – |
| EV/EBITDA | 30.7× | – |
| P/FCF | 37.0× | – |
| FCF yield | 2.7% | – |
| Fair value | $65.85 | – |
| Margin of safety | −39.7% | – |
| Growth | ||
| Revenue growth (TTM) | 14.6% (better) | 6.1% |
| Revenue growth, 5Y average | 6.7% (better) | 6.2% |
| Net income growth (TTM) | −75.8% | – |
| EPS growth (TTM) | −75.0% | 52.3% (better) |
| EPS growth, 5Y average | 7.1% (better) | 6.9% |
| Profitability | ||
| Gross margin | 77.8% (better) | 68.0% |
| Operating margin | 22.3% (better) | 12.9% |
| Net margin | 15.4% | – |
| FCF margin | 22.0% | – |
| Return on equity | 9.5% | – |
| Return on invested capital | 14.3% (better) | 13.0% |
| Financial health | ||
| Debt / equity | 0.06 (better) | 0.10 |
| Net debt / EBITDA | −2.26 | −0.31 |
| Interest coverage | – | 5.7× |
| Current ratio | 4.52 (better) | 2.14 |
| Altman Z-score | 12.90 | – |
| Piotroski F-score | 5 | – |
| Dividends and buybacks | ||
| Buyback yield | 2.3% | – |
| Shareholder yield | 2.3% | – |
| Ownership | ||
| Held by institutions | 91.0% | 4.2% |
| Held by insiders | 0.22% | 25.1% |
| Insider net buying, 12 months | −$27.7M | – |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 1.7% | – |
Go deeper
- EW stock overview
- EW income statement
- EW valuation and score
- SNN stock overview
- SNN income statement
- SNN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.